Vir Biotechnology, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Marianne De Backer
- Full Time Employees
- 367
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 499 Illinois Street San Francisco CA United States of America 94158
- IPO Date
- Oct 11, 2019
- CIK
- 0001706431
- Website
- vir.bio
- Similar Companies
- Business
- Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company that leverages immunology platforms to discover, develop and commercialize treatments for serious infectious diseases and oncology indications; its core technologies include a next-generation antibody platform and the PRO-XTEN protease-releasable masking technology exclusively licensed from Sanofi for oncology and infectious diseases. The company offers a deep pipeline of candidates such as tobevibart (an antibody incorporating Xencor's Xtend and other Fc technologies) combined with elebsiran for chronic hepatitis delta virus treatment in Phase 3 trials; VIR-5818, a dual-masked HER2-targeted T-cell engager in Phase 1 dose escalation with pembrolizumab for solid tumors; VIR-5500, a PSMA-targeted T-cell engager in Phase 1 with androgen receptor pathway inhibitors for prostate cancer; VIR-5525, an EGFR-targeted T-cell engager in Phase 1 monotherapy or with pembrolizumab; and preclinical efforts including undisclosed PRO-XTEN T-cell engagers, HIV cure antibodies with the Gates Foundation, and influenza A programs. Founded in 2016 and headquartered at 499 Illinois Street, Suite 500, in San Francisco, California, Vir Biotechnology operates primarily in the United States and Europe, targeting unmet needs in virology (hepatitis B/D, HIV, influenza, tuberculosis) and immuno-oncology with monoclonal antibodies, T-cell engagers, siRNA therapies and innate immunity modulators; it generates revenue from collaborations, grants and licenses. Recent developments include accelerated enrollment completion in the ECLIPSE 1 Phase 3 trial for hepatitis delta two months ahead of schedule, ongoing momentum in ECLIPSE 2 and 3 trials positioning for regulatory submissions, a planned comprehensive data update for influenza A candidate VIR-5500 in Q1 2026, expansion into first-line prostate cancer via a VIR-5500/ARPI combination study, a $250 million funding round at a $4.2 billion valuation bringing total raised to $821 million, and sustained strategic partnerships with GlaxoSmithKline, Alnylam Pharmaceuticals, Brii Biosciences, MedImmune and Sanofi to support pipeline advancement.
Company News
Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR
ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
Vir Biotechnology Q2 Earnings Call Highlights
Vir Biotechnology Q2 Earnings Call Highlights
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Vir Biotechnology Announces Chief Financial Officer Transition
Vir Biotechnology Announces Chief Financial Officer Transition
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript